Biomedicine has been listed as a "new emerging pillar industry," and tracking indices may have long-term industrial trends. The ICBCCS CNI HK Connect Innovative Drugs ETF (159217) helps investors to easily position themselves

Biomedicine has been listed as an emerging pillar industry, signaling industrial upgrading. The R&D capabilities of innovative drugs have been recognized, and the commercialization prospects are promising. A certain pharmaceutical company has been acquired by an overseas giant, validating the NewCo business model. Brokers believe that concerns in the BD market will ease, and the probability of BD scale shrinking is low. As industry profitability improves, commercialization will become the core of future pricing. The CNI HK Connect Innovative Drug Index may welcome a Davis double-hit opportunity, and the ICBCCS Innovative Drug ETF (159217) will help investors lay out low-cost investments